Deficiency of early components of the classical complement pathway

At a Glance

Deficiency of early components in the classical complement pathway is a category of congenital immunodeficiency diseases characterized by a lack of quantity or function of early complement components such as C1, C2, and C4.

Representative manifestations can include recurrent bacterial infections, and autoimmune symptoms similar to systemic lupus erythematosus may also be present.

How the Disease Works

It usually occurs due to pathological mutations in the genes that produce the relevant complement components, and the inheritance pattern may vary depending on the deficient component.

A deficiency in early complement components can lead to impaired complement activation of the classical pathway, as well as reduced functions in microbial opsonization/clearance and immune complex processing.

Patterns Vary by Person

Clinical presentation varies greatly among individuals depending on complement component deficiencies, residual complement function, degree of infection exposure, and accompanying genetic/immune factors.

Broad framework of diagnosis and management

Infections may be prominent in childhood but can persist into adulthood, and autoimmune or inflammatory problems may appear first.

Diagnosis involves a comprehensive assessment of the history of recurrent infections and autoimmune symptoms, complement function tests, and individual complement component measurement results, with genetic testing added if necessary.

Current stage of treatment

Complement test results may be influenced by the state of infection or inflammation, the timing of the test, and the specimen processing procedure; therefore, they are not considered definitive based on a single result alone.

Management focuses on preventing infection, ensuring prompt treatment when infections occur, reviewing vaccinations, and conducting individual assessments for autoimmune and organ complications.

Treatment focuses on preventing infection risk and immune abnormalities and managing manifested complications, rather than uniformly supplementing deficient complement components.

How to read clinical trials

In follow-up observations, the frequency and severity of infection, autoimmune activity, and the presence of organ damage must be monitored, and clinical trial results must be interpreted carefully, considering the participating patients and study conditions.

Points to verify in clinical encounters

In clinical practice, it is important to check the type, frequency, and severity of infections, autoimmune symptoms, family history, vaccination history, complement/genetic test results, and current medications together.